Synaptogenix, Inc. (SNPX)

USD 2.57

(-5.51%)

Market Cap (In USD)

3.48 Million

Revenue (In USD)

-

Net Income (In USD)

-6.03 Million

Avg. Volume

31.74 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.32-8.775
PE
-
EPS
-
Beta Value
1.427
ISIN
US87167T2015
CUSIP
87167T201
CIK
1571934
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alan J. Tuchman M.D., MBA(FAAN)
Employee Count
-
Website
https://www.synaptogen.com
Ipo Date
2020-12-08
Details
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.